Purpose A hospital protocol utilizing automatic dosage adjustments and pharmacist
consultations to optimize the use of certain medications in obese patients is described …

Background: Obesity and commonly associated comorbidities are known risk factors for the
development of infections. However, the intensity and duration of antimicrobial treatment are …

Context: An accurate and sensitive high-performance liquid chromatography-ultraviolet
(HPLC-UV) assay method was developed for the determination of two penicillins in oral …

As the prevalence of obesity increases worldwide, clinicians will be more and more
frequently confronted with obese, critically ill patients. Optimal administration of antibiotics is …

The aim of this article is to demonstrate extreme interindividual variability of
piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients …

В настоящее время в развитых странах ожирением страдают от 15 до 50% населения.
Пациенты с ожирением имеют более высокий риск возникновения инфекций, у них …

We present a case study of a 26-year-old morbidly obese man with a three-day history of
right leg pain and swelling. The swelling was associated with low grade fever. He was alert …

The increasing prevalence of obesity has led to a global epidemic and a growing public
health concern since obesity is a known risk factor for increased healthcare related morbidity …

Piperacillin–tazobactam (Zosyn, Tazocin) is a beta-lactam/beta-lactamase inhibitor
combination first licensed in 1993. The combination is formulated as a sodium salt in an 8: 1 …

Obesity is associated with an increased risk of infection. Unfortunately clinical trials
examining the safety and efficacy of antibiotics in obese patients are deficient. Thus …